pggptitle.gif (16097 bytes) 33277.jpg (4160 bytes)
This project is collaborated between The Forsyth Institute (TFI) and The Institute for Genomic Research (TIGR), and is funded by National Institute of Dental and Craniofacial Research (NIDCR)

To the dental research community

At present, more research papers, and more NIDR-funded grants are devoted to P. gingivalis than to other dental pathogens. Twenty-seven NIH grants with a primary focus on P. gingivalis (as of 1996) are listed below. Eleven of these grants are examining vaccine development, fourteen attempt to identify virulence factors, and fifteen are sequencing various P. gingivalis genes. The abstract and other information for each grant listed can be retrieved from the World Wide Web using the CRISP gopher (gopher://gopher.nih.gov/11/res/crisp). Total support for these grants is approximately $3,800,000 per year. A typical R01 to study either P. gingivalis functions directly or their effects on host tissues costs approximately $135,000 per year for 3 years, or approximately $400,000 to isolate and characterize 1 to 5 genes. Clearly by the R01 mechanism, sequencing gene by gene is both costly and time consuming. The NIDR is receptive to whole genome sequencing as a cost effective means for characterizing P. gingivalis and other dental pathogens.

NIH grants with a primary focus on Porphyromonas gingivalis.

Grant number

Investigator

Title

Vaccine

Virulence

Sequencing

K16DE001580010

MC Lynch

Superoxide dismutase in Porphyromonas gingivalis 381

+

+

K16DE002790002

AA Decarlo

Porphyromonas gingivalis activator of collagenolysis

+

R01DE07256

MS Lantz

Fibrinogen binding and virulence of P. gingivalis

+

+

R01DE07496

A Progulske-Fox

Surface antigens of oral Bacteroides species

+

+

R01DE08293

HK Kuramitsu

P gingivalis virulence--molecular genetic analysis

+

+

P01DE08555

RC Page

Humoral immunity and periodontal disease

+

P01DE085550001

RC Page

Humoral immunity and periodontal disease

+

P01DE085550003

R Persson

Humoral immunity and periodontal disease

+

P01DE085550005

RP Darveau

Humoral immunity and periodontal disease

+

R01DE09161

CA Genco

Hemin utilization by P. gingivalis

+

+

R01DE09426

PM Flood

Immunogenicity of fimbrillin from B. gingivalis

+

+

R29DE09439

RJ Lamont

Colonization mechanisms of periodontal pathogens

+

+

R29DE09602

RE Schifferle

B. gingivalis polysaccharides--structure and function

+

+

R29DE09845

JM Novak

P. gingivalis membrane blebs-modulators of PMN function

P50DE103060006

T Bramanti

Porphyromonas gingivalis-fibronectin interactions

R01DE10467

EJ Leys

Molecular & population genetics of periodontal pathogens

+

+

R01DE10510

MJ Duncan

P. gingivalis genes involved in attachment to epithelial cells

+

+

R29DE10607

J Katz

Microbial/host immune regulation in periodontal disease

+

P50DE107030003

FL Macrina

Molecular genetic studies of Porphyromonas gingivalis proteases

+

+

R29DE10728

PJ Baker

Murine host response to Porphyromonas gingivalis

R29DE10861

H Hosseinzadeh

Superantigens in periodontal diseases

+

R03DE10913

MC Roberts

Antibiotic resistance in periodontal pathogens

+

+

R01DE10963

TA Brown

Oral immunization with P. gingivalis virulence antigen

+

R01DE10994

JD Hillman

Isolation and testing of P. gingivalis virulence genes

+

+

R01De11111

RJ Lamont

P. gingivalis interactions with gingival epithelial cells

+

+

R01DE1117

DE Lopatin

Immunodominant stress proteins of P gingivalis

+

+

R03DE11313

TD Connell

A recombinant Porphyromonas gingivalis vaccine

+

+

Porphyromonas gingivalis is clearly implicated in adult forms of periodontitis. This project will produce the sequence of all virulence determinants and protein antigens, potential targets for disease prevention strategies such as vaccine or drug therapies. Periodontal diseases are currently treated primarily by surgery and tooth scaling. The Porphyromonas gingivalis genome project will hasten a switch to antibiotic or vaccine therapies which will change the delivery of periodontal therapy as significantly as the antimicrobial therapy for Helicobacter pylori has changed treatment of gastric ulcers.


This page is created and maintained by Drs. Margaret Duncan, Floyd Dewhirst, and Tsute Chen, Department of Molecular Genetics, The Forsyth Institute .

Last modified on 02/20/2002

Copyright 2000, 2001, 2002 by The Forsyth Institute